Edgewise Therapeutics Inc Aktie News

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on September 30, 2025, Edgewise granted inducement stock options to purchase a total of 247,000 shares of Edgewise's ...

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS).

BOULDER, Colo. , Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on August 29, 2025, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's com...

Investors can contact the law firm at no cost to learn more about recovering their losses

–  Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – –  Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy – –  Advanced the Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (...

BOULDER, Colo. , Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on July 31, 2025, Edgewise granted inducement stock options to purchase a total of 84,250 shares of Edgewise's common...

– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings  – – Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker – – Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 – –  Edgewise leadership to...

BOULDER, Colo. , June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.